ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.35+0.10 (+8.00%)
Close on Nov 17, 2026Market cap $172.35MP/E –Yield –
ADC Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
ADC Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$100.52M. For fiscal 2025 it was -$141.17M. The highest annual figure on record is -$118.69M in fiscal 2023.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$141.17M | – |
| FY2024 | Dec 31, 2024 | -$123.84M | – |
| FY2023 | Dec 31, 2023 | -$118.69M | – |
| FY2022 | Dec 31, 2022 | -$138.31M | – |
| FY2021 | Dec 31, 2021 | -$233.38M | – |
| FY2020 | Dec 31, 2020 | -$168.73M | – |
| FY2019 | Dec 31, 2019 | -$121.58M | – |
| FY2018 | Dec 31, 2018 | -$121.36M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$27.88M | – |
| Q2 FY2026 | Jun 30, 2026 | -$11.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.71M | – |
| Q4 FY2025 | Dec 31, 2025 | -$31.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.09M | – |
| Q1 FY2025 | Mar 31, 2025 | -$56.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.85M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$44.10M | – |
| Q4 FY2023 | Dec 31, 2023 | -$31.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$36.67M | -1770.8% |
| Q2 FY2023 | Jun 30, 2023 | -$34.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.39M | – |
| Q4 FY2022 | Dec 31, 2022 | -$53.61M | – |
| Q3 FY2022 | Sep 30, 2022 | $2.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$53.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$33.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$61.63M | – |
| Q3 FY2021 | Sep 30, 2021 | -$58.59M | – |
| Q2 FY2021 | Jun 30, 2021 | -$58.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$55.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$51.69M | – |
| Q3 FY2020 | Sep 30, 2020 | -$44.29M | – |
| Q2 FY2020 | Jun 30, 2020 | -$40.65M | – |
| Q1 FY2020 | Mar 31, 2020 | -$32.10M | – |
See a number that looks wrong?